LIPELLA PHARMACEUTICALS INC (LIPO) Fundamental Analysis & Valuation

NASDAQ:LIPO • US53630L2097

2.36 USD
-0.35 (-12.75%)
At close: Jun 18, 2025
1.8001 USD
-0.56 (-23.72%)
After Hours: 6/18/2025, 8:03:30 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This LIPO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LIPO. LIPO was compared to 519 industry peers in the Biotechnology industry. LIPO has a great financial health rating, but its profitability evaluates not so good. LIPO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. LIPO Profitability Analysis

1.1 Basic Checks

  • LIPO had negative earnings in the past year.
  • In the past year LIPO has reported a negative cash flow from operations.
  • LIPO had negative earnings in each of the past 5 years.
  • LIPO had a negative operating cash flow in each of the past 5 years.
LIPO Yearly Net Income VS EBIT VS OCF VS FCFLIPO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M -5M

1.2 Ratios

  • With a Return On Assets value of -105.66%, LIPO is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
  • The Return On Equity of LIPO (-125.78%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -105.66%
ROE -125.78%
ROIC N/A
ROA(3y)-120.13%
ROA(5y)-91.9%
ROE(3y)-154.59%
ROE(5y)-121.63%
ROIC(3y)N/A
ROIC(5y)N/A
LIPO Yearly ROA, ROE, ROICLIPO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LIPO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIPO Yearly Profit, Operating, Gross MarginsLIPO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. LIPO Health Analysis

2.1 Basic Checks

  • LIPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LIPO has more shares outstanding
  • LIPO has less shares outstanding than it did 5 years ago.
  • There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LIPO Yearly Shares OutstandingLIPO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
LIPO Yearly Total Debt VS Total AssetsLIPO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

  • LIPO has an Altman-Z score of 0.93. This is a bad value and indicates that LIPO is not financially healthy and even has some risk of bankruptcy.
  • LIPO has a Altman-Z score of 0.93. This is in the better half of the industry: LIPO outperforms 65.59% of its industry peers.
  • There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.93
ROIC/WACCN/A
WACC8.93%
LIPO Yearly LT Debt VS Equity VS FCFLIPO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

  • LIPO has a Current Ratio of 6.21. This indicates that LIPO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 6.21, LIPO is in the better half of the industry, outperforming 62.01% of the companies in the same industry.
  • A Quick Ratio of 6.21 indicates that LIPO has no problem at all paying its short term obligations.
  • The Quick ratio of LIPO (6.21) is better than 62.54% of its industry peers.
Industry RankSector Rank
Current Ratio 6.21
Quick Ratio 6.21
LIPO Yearly Current Assets VS Current LiabilitesLIPO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. LIPO Growth Analysis

3.1 Past

  • LIPO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -56.74%.
  • The Revenue has grown by 8.88% in the past year. This is quite good.
  • LIPO shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.04% yearly.
EPS 1Y (TTM)-56.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.42%
Revenue 1Y (TTM)8.88%
Revenue growth 3Y27.4%
Revenue growth 5Y-5.04%
Sales Q2Q%-11.31%

3.2 Future

  • Based on estimates for the next years, LIPO will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.87% on average per year.
  • Based on estimates for the next years, LIPO will show a very negative growth in Revenue. The Revenue will decrease by -41.42% on average per year.
EPS Next Y33.76%
EPS Next 2Y-48.97%
EPS Next 3Y19.87%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LIPO Yearly Revenue VS EstimatesLIPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
LIPO Yearly EPS VS EstimatesLIPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. LIPO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LIPO. In the last year negative earnings were reported.
  • Also next year LIPO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIPO Price Earnings VS Forward Price EarningsLIPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIPO Per share dataLIPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LIPO's earnings are expected to grow with 19.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.97%
EPS Next 3Y19.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LIPO Dividend Analysis

5.1 Amount

  • No dividends for LIPO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LIPO Fundamentals: All Metrics, Ratios and Statistics

LIPELLA PHARMACEUTICALS INC

NASDAQ:LIPO (6/18/2025, 8:03:30 PM)

After market: 1.8001 -0.56 (-23.72%)

2.36

-0.35 (-12.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28
Earnings (Next)N/A
Inst Owners1.41%
Inst Owner Change0%
Ins Owners6.52%
Ins Owner Change0%
Market Cap10.55M
Revenue(TTM)519.90K
Net Income(TTM)-5.13M
Analysts82.86
Price Target10.2 (332.2%)
Short Float %0.06%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.29
P/FCF N/A
P/OCF N/A
P/B 2.59
P/tB 2.59
EV/EBITDA N/A
EPS(TTM)-4.1
EYN/A
EPS(NY)-17.77
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.12
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -105.66%
ROE -125.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.13%
ROA(5y)-91.9%
ROE(3y)-154.59%
ROE(5y)-121.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.21
Quick Ratio 6.21
Altman-Z 0.93
F-Score5
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.42%
EPS Next Y33.76%
EPS Next 2Y-48.97%
EPS Next 3Y19.87%
EPS Next 5YN/A
Revenue 1Y (TTM)8.88%
Revenue growth 3Y27.4%
Revenue growth 5Y-5.04%
Sales Q2Q%-11.31%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.41%
OCF growth 3YN/A
OCF growth 5YN/A

LIPELLA PHARMACEUTICALS INC / LIPO FAQ

What is the fundamental rating for LIPO stock?

ChartMill assigns a fundamental rating of 2 / 10 to LIPO.


Can you provide the valuation status for LIPELLA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to LIPELLA PHARMACEUTICALS INC (LIPO). This can be considered as Overvalued.


Can you provide the profitability details for LIPELLA PHARMACEUTICALS INC?

LIPELLA PHARMACEUTICALS INC (LIPO) has a profitability rating of 0 / 10.


How financially healthy is LIPELLA PHARMACEUTICALS INC?

The financial health rating of LIPELLA PHARMACEUTICALS INC (LIPO) is 7 / 10.